EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Prognostic Value of the Systemic Immune-Inflammation Index in Advanced Endometrial Cancer Treated with Pembrolizumab–Lenvatinib: A Retrospective Real-World Study

Eleonora Palluzzi, Amedeo Cefaliello, Olga Martelli, Mariagrazia Distefano, Carolina Maria Sassu iD, Valentina Weger, Serena Maria Boccia, Laura Vertechy, Giorgia Russo iD, Luca Romano, Giacomo Corrado iD, Carolina Bottoni und 5 weitere

Current Oncology · 23.07.2026 · 33 (8) · 441

DOI: 10.3390/curroncol33080441 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Current Oncology, online erschienen am 23.07.2026. Verfasst von Eleonora Palluzzi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento Scienze della Salute della Donna e del Bambino, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, 00168 Rome, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Endometrial Neoplasms, Inflammation. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The prognostic role of the Systemic Immune-Inflammation Index (SII) in patients with endometrial cancer (EC) treated with pembrolizumab plus lenvatinib (Len-Pem) is unknown. In this study, the association between baseline SII and progression-free survival (PFS) was evaluated.

Methods

This is a monocentric, observational, retrospective/ambispective study including patients with advanced, recurrent, or metastatic mismatch repair proficient (pMMR) EC treated with Len-Pem.

Results

Fifty-three patients were enrolled, with a median age of 64 years. Median PFS in the overall population was 7.1 months; median OS was 15 months. Patients with baseline SII ≤ 540 had significantly longer PFS (12.5 months) compared to those with SII > 540 (5.5 months; HR 2.94, p = 0.004). Higher SII was also significantly associated with increased risk of specific toxicities, including nausea, anorexia, and vomiting. The Overall Response Rate (ORR) was 42%, and Disease Control Rate (DCR) was 71%.

Conclusion

Our real-world study supports the hypothesis-generation of a prognostic role for SII in predicting outcomes and toxicity in EC patients treated with Len-Pem. SII may serve as a cost-effective, accessible biomarker to stratify patients and hypothetically guide clinical decision-making. Further prospective studies are warranted to validate its clinical utility and to optimize dosing strategies that balance efficacy and tolerability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsEndometrial NeoplasmsInflammationPhenylurea CompoundsQuinolinesAgedAged, 80 and overFemaleHumansMiddle AgedPrognosisRetrospective Studies

Stichwörter der Autor:innen

endometrial cancerlenvatinibpembrolizumabsystemic inflammation index

Substanzen

Antibodies, Monoclonal, HumanizedlenvatinibpembrolizumabPhenylurea CompoundsQuinolines

Autor:innen und Institutionen

  • Dipartimento Scienze della Salute della Donna e del Bambino, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, 00168 Rome, Italy.
  • Dipartimento Scienze della Vita e Sanità Pubblica, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
  • Unit of Medical Oncology, Santa Maria della Misericordia Hospital, 06156 Perugia, Italy.
  • Facility of Epidemiology and Biostatistics-GSTeP, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, 00168 Rome, Italy.
  • Department of Obstetrics and Gynecology, Innsbruck Medical University, 6020 Innsbruck, Austria.

ORCID-Profile: Carolina Maria Sassu, Giorgia Russo, Giacomo Corrado, Christian Marth, Anna Fagotti

Zitieren

APA

Palluzzi, E., Cefaliello, A., Martelli, O., Distefano, M., Sassu, C. M., Weger, V., Boccia, S. M., Vertechy, L., Russo, G., Romano, L., Corrado, G., Bottoni, C., Giannarelli, D., Marth, C., Fagotti, A., Fanfani, F., & Marchetti, C. (2026). Prognostic Value of the Systemic Immune-Inflammation Index in Advanced Endometrial Cancer Treated with Pembrolizumab–Lenvatinib: A Retrospective Real-World Study. Current Oncology, 33(8), 441. https://doi.org/10.3390/curroncol33080441

Vancouver

Palluzzi E, Cefaliello A, Martelli O, Distefano M, Sassu CM, Weger V, et al. Prognostic Value of the Systemic Immune-Inflammation Index in Advanced Endometrial Cancer Treated with Pembrolizumab–Lenvatinib: A Retrospective Real-World Study. Current Oncology. 2026;33(8):441. doi:10.3390/curroncol33080441

BibTeX
@article{Palluzzi2026,
  author = {Palluzzi, Eleonora and Cefaliello, Amedeo and Martelli, Olga and Distefano, Mariagrazia and Sassu, Carolina Maria and Weger, Valentina and Boccia, Serena Maria and Vertechy, Laura and Russo, Giorgia and Romano, Luca and Corrado, Giacomo and Bottoni, Carolina and Giannarelli, Diana and Marth, Christian and Fagotti, Anna and Fanfani, Francesco and Marchetti, Claudia},
  title = {Prognostic Value of the Systemic Immune-Inflammation Index in Advanced Endometrial Cancer Treated with Pembrolizumab–Lenvatinib: A Retrospective Real-World Study},
  journal = {Current Oncology},
  year = {2026},
  volume = {33},
  number = {8},
  pages = {441},
  doi = {10.3390/curroncol33080441}
}
Kostenlos starten →